Literature DB >> 21601870

Lymphoplasmacytic endotheliitis and anterior uveitis in sheep infected experimentally with rift valley fever virus.

I Galindo-Cardiel1, N Busquets, R Velarde, F X Abad, D Solanes, R Rivas, R Valle, A Brun, M Domingo.   

Abstract

Lymphoplasmacytic endotheliitis and anterior uveitis was diagnosed in four lambs infected experimentally with field isolates of Rift Valley fever virus (RVFV). Formalin-fixed and paraffin wax-embedded tissue from these animals was investigated by histopathology and quantitative real time reverse transcriptase polymerase chain reaction. To our knowledge, this is the first pathological description of this ocular manifestation of RVFV infection in ruminants, although these lesions have been described in man.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21601870     DOI: 10.1016/j.jcpa.2011.03.013

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  3 in total

1.  Potential for autoimmune pathogenesis of Rift Valley Fever virus retinitis.

Authors:  Shoshana Newman-Gerhardt; Samuel Muiruri; Eric Muchiri; Clarence J Peters; John Morrill; Alexander H Lucas; Charles H King; James Kazura; Angelle Desiree LaBeaud
Journal:  Am J Trop Med Hyg       Date:  2013-08-05       Impact factor: 2.345

Review 2.  A Review of Bunyamwera, Batai, and Ngari Viruses: Understudied Orthobunyaviruses With Potential One Health Implications.

Authors:  M Fausta Dutuze; Manassé Nzayirambaho; Christopher N Mores; Rebecca C Christofferson
Journal:  Front Vet Sci       Date:  2018-04-12

Review 3.  The challenging management of Rift Valley Fever in humans: literature review of the clinical disease and algorithm proposal.

Authors:  Emilie Javelle; Alexandre Lesueur; Vincent Pommier de Santi; Franck de Laval; Thibault Lefebvre; Guillaume Holweck; Guillaume André Durand; Isabelle Leparc-Goffart; Gaëtan Texier; Fabrice Simon
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-01-22       Impact factor: 3.944

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.